Related Experiment Video
Updated: Jan 21, 2026

Applying an eMASS Customization Program as a Research Tool to Evaluate Consumer Benefits
Published on: September 27, 2019
Decomposing the effect of drug benefit program on antihypertensive medication adherence among the elderly in urban
Xiaochen Ma1, Yuji Zhang2, Mei Zhang2
1China Center for Health Development Studies, Peking University, Beijing 100000, People's Republic of China.
Purpose:
Hypertension is a rapidly growing epidemic in People's Republic of China, yet it remains inadequately controlled. This study aimed to identify the relative contributions of program effects and patients' characteristics to the differences in antihypertensive medication nonadherence between drug benefit program enrollees and non-enrollees.
Patients And Methods:
Data were from a cross-sectional survey of 1,969 community-dwelling elderly adults with hypertension. Self-reported adherence was measured following previous studies in People's Republic of China. The Blinder-Oaxaca nonlinear decomposition method was used to identify the relative contributions of program effects and patients' individual characteristics.
Results:
Eleven percent of the drug benefit program enrollees were nonadherent to their medication, while 17% of non-enrollees were. Blinder-Oaxaca decomposition identified that over 60% of the gap between the two groups was due to the program effects (P=0.024). The rest could be explained by differences in observable characteristics (P<0.001), such as diabetic status, duration of hypertension, and blood pressure control.
Conclusion:
The study confirmed that drug benefit program enrollees were more likely to be adherent to their antihypertensive medication than non-enrollees in the context of People's Republic of China.
Related Concept Videos
Antihypertensive Drugs: Vasodilators
Antihypertensive Drugs: Action of Diuretics
Antihypertensive Drugs: Thiazide-Class Diuretics
Antihypertensive Drugs: Potassium-Sparing Diuretics
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Types of β-Blockers

